Nkarta, Inc. Profile Avatar - Palmy Investing

Nkarta, Inc.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cel…

Biotechnology
US, South San Francisco [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Nkarta, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Nkarta, Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Nkarta, Inc..

End of NKTX's Analysis
CIK: 1787400 CUSIP: 65487U108 ISIN: US65487U1088 LEI: - UEI: -
Secondary Listings
NKTX has no secondary listings inside our databases.